Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children’s Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
तुलना करने के लिए मीट्रिक्स | SRPT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSRPTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.5x | −3.3x | −0.5x | |
PEG अनुपात | 0.01 | 0.01 | 0.00 | |
क़ीमत/बुक | 1.6x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.8x | 4.3x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 13.7% | 11.0% | 51.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | −6.1% | 7.3% | अनलॉक करें |